GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced that the US Government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, enabling further nationwide access to sotrovimab for patients.
GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab
January 14, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022